|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||28.44 - 28.44|
|52-week range||25.57 - 34.25|
|Beta (5Y monthly)||0.81|
|PE ratio (TTM)||10.92|
|Forward dividend & yield||1.38 (4.72%)|
|Ex-dividend date||29 Sept 2022|
|1y target est||N/A|
TAK vs. ZTS: Which Stock Is the Better Value Option?
The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
TOKYO (Reuters) -Japan's biggest drugmaker Takeda Pharmaceutical Co reported a sharp drop in first-quarter profit on Thursday, reflecting one-off gains a year earlier, while maintaining annual earnings forecasts that are buoyed by the yen's decline. In the first quarter of last fiscal year, Takeda benefited from a one-time gain of 131.4 billion yen when it sold off its diabetes assets to refocus on core businesses following its acquisition of Shire Plc. The next major driver for Takeda's earnings and shares may be a decision by European regulators, expected later this year, on the company's experimental vaccine for Dengue fever.